These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26995758)

  • 41. A QCM-D and SAXS Study of the Interaction of Functionalised Lyotropic Liquid Crystalline Lipid Nanoparticles with siRNA.
    Tajik-Ahmadabad B; Mechler A; Muir BW; McLean K; Hinton TM; Separovic F; Polyzos A
    Chembiochem; 2017 May; 18(10):921-930. PubMed ID: 28233412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chitosan-lipid nanoparticles (CS-LNPs): Application to siRNA delivery.
    Tezgel Ö; Szarpak-Jankowska A; Arnould A; Auzély-Velty R; Texier I
    J Colloid Interface Sci; 2018 Jan; 510():45-56. PubMed ID: 28934610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
    Tao W; Davide JP; Cai M; Zhang GJ; South VJ; Matter A; Ng B; Zhang Y; Sepp-Lorenzino L
    Mol Ther; 2010 Sep; 18(9):1657-66. PubMed ID: 20628357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
    J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract.
    Ball RL; Bajaj P; Whitehead KA
    Sci Rep; 2018 Feb; 8(1):2178. PubMed ID: 29391566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cuboplexes: Topologically Active siRNA Delivery.
    Kim H; Leal C
    ACS Nano; 2015 Oct; 9(10):10214-26. PubMed ID: 26390340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization.
    Ball RL; Bajaj P; Whitehead KA
    Int J Nanomedicine; 2017; 12():305-315. PubMed ID: 28115848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.
    Ewe A; Höbel S; Heine C; Merz L; Kallendrusch S; Bechmann I; Merz F; Franke H; Aigner A
    Drug Deliv Transl Res; 2017 Apr; 7(2):206-216. PubMed ID: 27334279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles.
    Mo Y; Cheng MHY; D'Elia A; Doran K; Ding L; Chen J; Cullis PR; Zheng G
    ACS Nano; 2023 Mar; 17(5):4688-4703. PubMed ID: 36853331
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution.
    Nakamura T; Kawai M; Sato Y; Maeki M; Tokeshi M; Harashima H
    Mol Pharm; 2020 Mar; 17(3):944-953. PubMed ID: 31990567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
    Jayaraman M; Ansell SM; Mui BL; Tam YK; Chen J; Du X; Butler D; Eltepu L; Matsuda S; Narayanannair JK; Rajeev KG; Hafez IM; Akinc A; Maier MA; Tracy MA; Cullis PR; Madden TD; Manoharan M; Hope MJ
    Angew Chem Int Ed Engl; 2012 Aug; 51(34):8529-33. PubMed ID: 22782619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
    Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
    ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
    Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
    Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure of Lipid Nanoparticles Containing siRNA or mRNA by Dynamic Nuclear Polarization-Enhanced NMR Spectroscopy.
    Viger-Gravel J; Schantz A; Pinon AC; Rossini AJ; Schantz S; Emsley L
    J Phys Chem B; 2018 Feb; 122(7):2073-2081. PubMed ID: 29332384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticles.
    Zhao X; Liu Y; Song J; Yong H; Li L; Shen Y; Hubbard RD; Kohlbrenner WE; Zhou J; Cluff KD; Skoug JW
    J Drug Target; 2012 Apr; 20(3):281-9. PubMed ID: 22214439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.
    Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D
    Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single pot organic solvent-free thermocycling technology for siRNA-ionizable LNPs: a proof-of-concept approach for alternative to microfluidics.
    De A; Ko YT
    Drug Deliv; 2022 Dec; 29(1):2644-2657. PubMed ID: 35949146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation.
    Chen D; Love KT; Chen Y; Eltoukhy AA; Kastrup C; Sahay G; Jeon A; Dong Y; Whitehead KA; Anderson DG
    J Am Chem Soc; 2012 Apr; 134(16):6948-51. PubMed ID: 22475086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Importance of Process Parameters Influencing the Mean Diameters of siRNA-Containing Lipid Nanoparticles (LNPs) on the in Vitro Activity of Prepared LNPs.
    Nakamura K; Aihara K; Ishida T
    Biol Pharm Bull; 2022; 45(4):497-507. PubMed ID: 35370275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.